Development of Cytomegalovirus-Based Vaccines Against Melanoma
Abstract
The presence of tumor infiltrating CDS+ T cells is associated with tumor regression. Cytomegalovirus fCMV infection elicits a robust and long-lasting CDS+ T cell response, which makes CMV a potentially promising vaccine vector against cancer. In the last funding period, we used recombinant murine CMV (MCMV) strains as prophylactic and therapeutic vaccines in an aggressive Bl6 lung metastatic melanoma model. We engineered MCMV to express a modified Bl6melanoma antigen gplOO (MCMV-gplOOKGP) . Immunization with MCMV-gplOOKGP was highly effective in overcoming immune tolerance to self-antigen and induced a strong, long-lasting gplOO specific CDS+ T cell response even in the presence of pre-existing CMV immunity. Furthermore, both prophylactic and therapeutic vaccination of mice with MCMV-gplOOKGP effectively protected mice from highly aggressive lung Bl6-Fl0 melanoma. Collectively, our studies demonstrated that CMV is a promising vaccine vector to prevent and treat tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1035729
Entities
People
- Kamal Khanna
Organizations
- University of Connecticut